Literature DB >> 23541187

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status.

Shanker Swaminathan1, Shannon L Risacher2, Karmen K Yoder2, John D West2, Li Shen3, Sungeun Kim3, Mark Inlow4, Tatiana Foroud5, William J Jagust6, Robert A Koeppe7, Chester A Mathis8, Leslie M Shaw9, John Q Trojanowski9, Holly Soares10, Paul S Aisen11, Ronald C Petersen12, Michael W Weiner13, Andrew J Saykin14.   

Abstract

BACKGROUND: Apolipoprotein E (APOE) ε4 allele's role as a modulator of the relationship between soluble plasma amyloid beta (Aβ) and fibrillar brain Aβ measured by Pittsburgh compound B positron emission tomography ([(11)C]PiB PET) has not been assessed.
METHODS: Ninety-six Alzheimer's Disease Neuroimaging Initiative participants with [(11)C]PiB scans and plasma Aβ1-40 and Aβ1-42 measurements at the time of PET scanning were included. Regional and voxelwise analyses of [(11)C]PiB data were used to determine the influence of APOE ε4 allele on association of plasma Aβ1-40, Aβ1-42, and Aβ1-40/Aβ1-42 with [(11)C]PiB uptake.
RESULTS: In APOE ε4- but not ε4+ participants, positive relationships between plasma Aβ1-40/Aβ1-42 and [(11)C]PiB uptake were observed. Modeling the interaction of APOE and plasma Aβ1-40/Aβ1-42 improved the explained variance in [(11)C]PiB binding compared with using APOE and plasma Aβ1-40/Aβ1-42 as separate terms.
CONCLUSIONS: The results suggest that plasma Aβ is a potential Alzheimer's disease biomarker and highlight the importance of genetic variation in interpretation of plasma Aβ levels.
Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's Disease Neuroimaging Initiative; Alzheimer's disease; Amyloid beta; Apolipoprotein E; Mild cognitive impairment; Pittsburgh compound B; Plasma amyloid beta; Positron emission tomography

Mesh:

Substances:

Year:  2013        PMID: 23541187      PMCID: PMC3750076          DOI: 10.1016/j.jalz.2013.01.007

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  46 in total

1.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Authors:  Peder Buchhave; Lennart Minthon; Henrik Zetterberg; Asa K Wallin; Kaj Blennow; Oskar Hansson
Journal:  Arch Gen Psychiatry       Date:  2012-01

2.  Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier.

Authors:  Corbin Bachmeier; David Beaulieu-Abdelahad; Fiona Crawford; Michael Mullan; Daniel Paris
Journal:  J Mol Neurosci       Date:  2012-08-14       Impact factor: 3.444

3.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

4.  Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Authors:  Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

Review 5.  Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.

Authors:  G D Rabinovici; W J Jagust
Journal:  Behav Neurol       Date:  2009       Impact factor: 3.342

6.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

7.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

Review 8.  Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.

Authors:  John E Donahue; Conrad E Johanson
Journal:  J Neuropathol Exp Neurol       Date:  2008-04       Impact factor: 3.685

9.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

10.  Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain.

Authors:  Phillip B Jones; Kenneth W Adams; Anete Rozkalne; Tara L Spires-Jones; Tammy T Hshieh; Tadafumi Hashimoto; Christine A F von Armin; Mathew Mielke; Brian J Bacskai; Bradley T Hyman
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

View more
  26 in total

1.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 2.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

3.  High performance plasma amyloid-β biomarkers for Alzheimer's disease.

Authors:  Akinori Nakamura; Naoki Kaneko; Victor L Villemagne; Takashi Kato; James Doecke; Vincent Doré; Chris Fowler; Qiao-Xin Li; Ralph Martins; Christopher Rowe; Taisuke Tomita; Katsumi Matsuzaki; Kenji Ishii; Kazunari Ishii; Yutaka Arahata; Shinichi Iwamoto; Kengo Ito; Koichi Tanaka; Colin L Masters; Katsuhiko Yanagisawa
Journal:  Nature       Date:  2018-01-31       Impact factor: 49.962

4.  Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.

Authors:  Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel
Journal:  Alzheimers Dement       Date:  2016-11-18       Impact factor: 21.566

Review 5.  The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Authors:  Ju-Hee Kang; Magdalena Korecka; Michal J Figurski; Jon B Toledo; Kaj Blennow; Henrik Zetterberg; Teresa Waligorska; Magdalena Brylska; Leona Fields; Nirali Shah; Holly Soares; Robert A Dean; Hugo Vanderstichele; Ronald C Petersen; Paul S Aisen; Andrew J Saykin; Michael W Weiner; John Q Trojanowski; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

Review 6.  Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Authors:  Andrew J Saykin; Li Shen; Xiaohui Yao; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Vijay K Ramanan; Tatiana M Foroud; Kelley M Faber; Nadeem Sarwar; Leanne M Munsie; Xiaolan Hu; Holly D Soares; Steven G Potkin; Paul M Thompson; John S K Kauwe; Rima Kaddurah-Daouk; Robert C Green; Arthur W Toga; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

7.  Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

Authors:  Vincent Chouraki; Alexa Beiser; Linda Younkin; Sarah Rosner Preis; Galit Weinstein; Oskar Hansson; Ingmar Skoog; Jean-Charles Lambert; Rhoda Au; Lenore Launer; Philip A Wolf; Steven Younkin; Sudha Seshadri
Journal:  Alzheimers Dement       Date:  2014-09-10       Impact factor: 21.566

Review 8.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

9.  Blood Pressure Level Is Associated With Changes in Plasma Aβ1 -40 and Aβ1-42 Levels: A Cross-sectional Study Conducted in the Suburbs of Xi'an, China.

Authors:  Meilin She; Suhang Shang; Ningwei Hu; Chen Chen; Liangjun Dang; Ling Gao; Shan Wei; Kang Huo; Jingyi Wang; Jin Wang; Qiumin Qu
Journal:  Front Aging Neurosci       Date:  2021-06-04       Impact factor: 5.750

Review 10.  Genetic heterogeneity in Alzheimer disease and implications for treatment strategies.

Authors:  John M Ringman; Alison Goate; Colin L Masters; Nigel J Cairns; Adrian Danek; Neill Graff-Radford; Bernardino Ghetti; John C Morris
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.